Please assess the completion status of the following clinical trial:

Trial Title: Multimodal Imaging Analysis During Treatment With Bevacizumab in Patients With Recurrent Glioblastoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* World Health Organization performance index lower or equal to 3~* Estimated life expectancy greater than 3 months~* patient in whom the diagnosis of glioblastoma was histologically proven~* Patient with tumor progression of morphological magnetic resonance imagery evidenced by Pluri Disciplinary Meeting. This increase must meet the detailed criteria Response Assessment Neuro Oncology Working group : except in the case of a new lesion appearing outside of the field of radiotherapy, tumor progression can not therefore be defined on an magnetic resonance imagery performed in a period shorter than 12 weeks after the last day of radiotherapy (see criteria Response Assessment Neuro Oncology Working Group detailed chapter 2-1 B)~* Patient with unilateral tensor above injury at baseline (in order to have in each case a tumor region of interest area and an area equivalent region of interest contralateral healthy tissue) .~* Patient with measurable lesion at baseline, according to the criteria defined by the working group Respons Assessment Neuro Oncology. The lesion with contrast is measured two-dimensionally on T1 gadolinium in axial section. The two perpendicular diameters of red lead should be 10 mm and that at least two axial sections.~* Patient with progression after radiotherapy and have received at least one chemotherapy regimen (temodal)~* A patient in whom treatment with bevacizumab monotherapy~Exclusion Criteria:~* Pregnancy~* Exclusion criteria related to cons to the realization of positron emission tomography or magnetic resonance imagery : Weight greater than 120 kg, Foreign body incompatible with magnetic resonance imagery (eg metallic intraocular foreign body), Medical equipment installed incompatible with magnetic resonance imagery (eg pacemaker)~* Pregnant or lactating woman

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with glioblastoma (Type: EXPERIMENTAL): Patient with histologically proved glioblastoma diagnostic will receive the following interventions :~* Cerebral magnetic resonance imagery~* Tomography emission positron with F-MISO~* Bevacizumab administration~* Clinical examination

Based on this trial design, predict the completion outcome and termination type (if applicable).